This website uses cookies to ensure that we give you the best experience on our website. Click here for more information.


Terms of Use

The information contained in this site is for healthcare professionals only.

I am not a healthcare professional I confirm to be a healthcare professional

Prolia® (denosumab) in women with postmenopausal osteoporosis

Postmenopausal osteoporosis may occur as a consequence of estrogen deficiency. As a result of bone loss and reduced bone strength, postmenopausal women are at increased risk of fractures. Prolia® (denosumab) is an osteoporosis medication that lowers the risk of vertebral fractures, non-vertebral fractures, and hip fractures in postmenopausal women and increase bone density. Adequate intake of calcium and vitamin D are important in reducing the risk of fragility fractures in these patients. 

Studies have shown that Prolia® (denosumab) effectively decreases fracture risk in postmenopausal women 

Prolia® (denosumab) treatment for osteoporosis has been compared with placebo in over postmenopausal 8,000 women. The main measure of efficacy in these women was the number of new fractures, particularly spinal fractures and hip fractures. Results were similar to or better than what has earlier been demonstrated for other drugs approved for the osteoporosis treatment in postmenopausal women at increased risk of fracture. The fact that women had a lower average body weight than men in studies (mean 69.8 vs. 85.2 kg) did not alter the pharmacokinetics of Prolia® (denosumab).

Prolia® (denosumab) treatment for osteoporosis has been compared with placebo in over 8,000 women.